header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

PREVENTION OF PERIPROSTHETIC OSSIFICATION WITH CELECOXIB



Abstract

Purpose: Periprosthetic ossification is a frequent complication of total hip arthroplasty and can have a major functional impact. Non-steroidal anti-inflammatory drugs (NSAID) can provide effective prevention but with a risk of morbidity. The purpose of this work was to evaluate the efficacy of an anti-Cox2 agent, cele-coxib, for this indication.

Material and methods: Total hip arthroplasty was performed in 42 patients with a relative (gastrointestinal) contraindication for the use of NSAID. These patients were given celecoxib (Celebrxy(r)) 200 mg bid starting the day before the operation and continuing for at least five days. A control group of 42 age- (±3 yr) and sex-matched patients who underwent surgery for the same indication performed by a surgeon with equivalent experience was also established. The control patients were given ketoprofen (Profénidy(r)) 50 mg qid for two days then 150 mg bid for five days. The approach, implant, and other adjuvant treatments were equivalent between the two groups. Ossifications were analysed on the follow-up films taken at least three months after surgery. The Brooker classification was used. The exact Fisher test was used for the statistical analysis.

Results: The two groups each included 31 women and eleven men, mean age being the same in the two groups (67.12 yrs). Mean follow-up was very similar (8.44 vs 8.6 months). Aetiologies were: primary degenerative hip (n=30), degenerative hip disease after dysplasia (n=9), sequela of infantile arthritis (n=1), revision total hip prosthesis (n=2). Two patients in each group interrupted their treatment between day 2 and 4 because of intolerance. There were no cases of significant haematoma in either group. No ossification > grade 2 was observed. The overall rate of ossification was 42.5% in the control group versus 48.6% in the celecoxib group. The rate of grade 2 ossifications was 8% in the cele-coxib group versus 12% in the control group. These rates were not significantly different (Fisher’s exact test= 0.6).

Discussion: In this study, celecoxib and ketoprofen were found to have equivalent efficacy for the prevention periprosthetic ossification. This is an interesting perspective in the probable hypothesis of less morbidity with anti-Cox 2 antiinflammatory drugs used in combination with an antalgesia protocol.

Correspondence should be addressed to SOFCOT, 56 rue Boissonade, 75014 Paris, France.